tetano
Editor, Senior Moderator
Expert Rev Anti Infect Ther
. 2024 Feb 1:1-9.
doi: 10.1080/14787210.2024.2309998. Online ahead of print. Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China
Pulin Li[SUP] 1 [/SUP], Ling Huang[SUP] 2 [/SUP], Rui Han[SUP] 1 [/SUP], Min Tang[SUP] 1 [/SUP], Guanghe Fei[SUP] 1 [/SUP], Daxiong Zeng[SUP] 3 4 [/SUP], Ran Wang[SUP] 1 [/SUP]
Affiliations
Background: Since December 2022, the Omicron variant has led to a widespread pandemic in China. The study was to explore the safety and effectiveness of Paxlovid for the treatment of coronavirus disease 2019 (COVID-19).
Research design and methods: We included patients at risk of developing severe COVID-19, all of whom exhibited mild to moderate symptoms and were admitted to three hospital centers. Patients were divided into two groups: one received Paxlovid alongside standard care, while the other was given only standard care. We compared clinical characteristics, hospital stay duration, and clinical outcomes between two groups. Multi-factor analysis determined the independent risk factors influencing the duration of hospitalization and disease progression.
Results: In the study, those treated with Paxlovid shorter hospital stays than those in the control group (p < 0.001). Multivariate analysis indicated that the absence of Paxlovid treatment was a distinct risk factor for hospitalizations lasting over 7 days (OR: 4.983, 95% CI: 3.828-6.486, p < 0.001) and 14 days (OR: 2.940, 95% CI: 2.402-3.597, p < 0.001).
Conclusion: Amid the Omicron outbreak, Paxlovid has proven to be a safe and effective treatment for reducing hospitalization durations for patients with mild to moderate COVID-19.
Keywords: COVID-19; Paxlovid; SARS-CoV-2; hospitalization; prognosis.
. 2024 Feb 1:1-9.
doi: 10.1080/14787210.2024.2309998. Online ahead of print. Safety and efficacy of Paxlovid in the treatment of adults with mild to moderate COVID-19 during the omicron epidemic: a multicentre study from China
Pulin Li[SUP] 1 [/SUP], Ling Huang[SUP] 2 [/SUP], Rui Han[SUP] 1 [/SUP], Min Tang[SUP] 1 [/SUP], Guanghe Fei[SUP] 1 [/SUP], Daxiong Zeng[SUP] 3 4 [/SUP], Ran Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 38300126
- DOI: 10.1080/14787210.2024.2309998
Background: Since December 2022, the Omicron variant has led to a widespread pandemic in China. The study was to explore the safety and effectiveness of Paxlovid for the treatment of coronavirus disease 2019 (COVID-19).
Research design and methods: We included patients at risk of developing severe COVID-19, all of whom exhibited mild to moderate symptoms and were admitted to three hospital centers. Patients were divided into two groups: one received Paxlovid alongside standard care, while the other was given only standard care. We compared clinical characteristics, hospital stay duration, and clinical outcomes between two groups. Multi-factor analysis determined the independent risk factors influencing the duration of hospitalization and disease progression.
Results: In the study, those treated with Paxlovid shorter hospital stays than those in the control group (p < 0.001). Multivariate analysis indicated that the absence of Paxlovid treatment was a distinct risk factor for hospitalizations lasting over 7 days (OR: 4.983, 95% CI: 3.828-6.486, p < 0.001) and 14 days (OR: 2.940, 95% CI: 2.402-3.597, p < 0.001).
Conclusion: Amid the Omicron outbreak, Paxlovid has proven to be a safe and effective treatment for reducing hospitalization durations for patients with mild to moderate COVID-19.
Keywords: COVID-19; Paxlovid; SARS-CoV-2; hospitalization; prognosis.